Drug Trial Radar · NCT06725381
A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
138
Planned (sponsor's estimate)
Start
Dec 17, 2024
Primary completion
Dec 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human (FIH), phase 1, multicenter, open-label study of SKB571 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity in adult subjects with advanced or metastatic solid tumor .
Conditions
- Solid Malignancies
Interventions
SKB571Drug
SKB571 for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects achieving Dose-limiting toxicity (DLT)Time frame: From data of initial dose until up to 21 days for treatment
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Bei Jing Cancer Hospital
Beijing, China · Not yet recruiting
Chongqing University Cancer Hospital
Chongqing, China · Recruiting
Shanghai East Hospital
Shanghai, China · Recruiting
Shanghai Pulmonary Hospital
Shanghai, China · Not yet recruiting
Zhongshan Hospital
Shanghai, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China · Recruiting
Hubei Cancer Hospital
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
The Affliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China · Recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Recruiting
Guangxi Medical University Cancer Hospital
Linyi, Shandong, China · Recruiting
Si Chuan Cancer Hospital
Chengdu, Sichuan, China · Recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.